GlassScriptPhysician profile
Julie Park
NPI 1235320516
$5,264.60
in general payments reported to CMS, 2019-2025
35 companies · $828 in 2025
The $828 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $543 · 2023: $1,726 · 2024: $1,449 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,904 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,903.78 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $939.78 | 2021-2025 | Rybrevant, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $726.64 | 2022-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $418.92 | 2021-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $399.99 | 2022-2025 | |
| Incyte Corporation | $244.63 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $238.82 | 2023 | Trodelvy |
| Beigene USA, INC. | $233.23 | 2022-2023 | Brukinsa |
| Seagen INC. | $225.49 | 2022-2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $175.21 | 2021-2025 | Enhertu |
| Abbvie INC. | $156.77 | 2023-2024 | |
| Pfizer INC. | $151.41 | 2024 | |
| Abbott Laboratories | $146.75 | 2021 | |
| Genentech USA, INC. | $145.34 | 2024-2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Beone Medicines USA, INC. | $129.20 | 2025 | Brukinsa |
| Celgene Corporation | $120.90 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $95.65 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $87.29 | 2023 | Epkinly, Imbruvica |
| Eisai INC. | $68.76 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.00 | 2024-2025 | Ninlaro, Iclusig |
| Servier Pharmaceuticals LLC | $50.55 | 2024 | |
| Exelixis INC. | $49.01 | 2021 | |
| Lilly USA, LLC | $48.74 | 2021-2025 | Jaypirca |
| Sumitomo Pharma America, INC. | $45.89 | 2023 | Myfembree |
| Regeneron Healthcare Solutions, INC. | $33.66 | 2022 | |
| Genmab U.S., INC. | $32.97 | 2025 | Epkinly |
| Medtronic, INC. | $29.44 | 2023 | Ligasure |
| Amgen INC. | $26.69 | 2022 | |
| Genzyme Corporation | $25.67 | 2023 | |
| Coherus Oncology, INC. | $24.89 | 2024 | |
| Astellas Pharma US INC | $23.67 | 2023 | Padcev |
| Array Biopharma INC | $23.13 | 2025 | Braftovi, Lorbrena, Mektovi |
| Pharmacosmos Therapeutics INC. | $22.55 | 2023 | Monoferric |
| Adaptive Biotechnologies Corporation | $20.91 | 2024 | Clonoseq |
| Novocure INC. | $19.57 | 2024 | Optune Lua (Novottf-200t) |
| Accord Healthcare, INC. | $16.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.